Form 4: AbbVie Director Robert J. Alpern Reports Changes in Beneficial Ownership

Director Robert J. Alpern reports acquisition of stock equivalent units in AbbVie through director fees and dividend reinvestment.

Summary

• Robert J. Alpern, a director of AbbVie Inc., filed a Form 4 on July 2, 2024, reporting changes in beneficial ownership.
• The earliest transaction date reported was June 30, 2024.
• Alpern acquired 43 stock equivalent units at a price of $171.52 due to director fees credited to stock equivalent unit accounts.
• These units are held in grantor trusts established by the director at Abbott Laboratories and AbbVie.
• The stock equivalent units earn the same return as if the fees were invested in AbbVie stock and will be paid in cash generally at age 65 or upon retirement from the respective boards.
• The balance of stock equivalent units owned following the reported transaction is 9,541, which includes units acquired through a dividend reinvestment feature.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects a director's continued investment in the company, but it's a routine transaction.

Positives

• The acquisition of stock equivalent units demonstrates the director's continued investment in AbbVie's future.
• Dividend reinvestment further increases the director's stake in the company.

Future Outlook

The stock equivalent units will be paid out in cash upon retirement or at age 65, reflecting a long-term investment strategy.

Industry Context

This filing is a routine disclosure of a director's transactions in company stock, providing transparency to investors.

Stakeholder Impact

• The disclosure provides transparency to shareholders regarding director's holdings.

Key Dates